Harrow, Inc. (NASDAQ: HROW) is an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies that are accessible and affordable. These pharmaceutical products are used in the U.S. in ophthalmic surgical procedures, such as cataract and refractive surgeries, as well as large and growing chronic eyecare markets, such as dry eye disease, glaucoma, allergies, and infections. Harrow and its affiliate ImprimisRx currently serve over 10,000 doctors, hospitals, and ambulatory service centers through an integrated national sales and customer service organization and efficient, scalable, and tech-enabled national production and distribution platforms licensed to do business in all 50 U.S. states. Harrow also holds large equity positions in Melt Pharmaceuticals, Surface Ophthalmics, and Eton Pharmaceuticals, all of which started as Harrow subsidiaries.
Data Provided by Refinitiv. Minimum 15 minutes delayed.